Search

ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.

Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.

Read more

Highlights of Past EHA (HOPE) Latin America (LA) 2023 - report

October 26, 2023 – São Paulo, Brazil

Meeting chairs:

A Almeida - President EHA

JF Comenalli Marques Jr - President ABHH

C Chiattone - President HEMO 2023

This year, the HOPE LA meeting was held in collaboration with the Associação Brasileira de Hematologia Hemoterapia e…

Read more

Position of EHA on Research Funding

 

The challenge
The cost of biomedical research is great, but the cost of disease is immense. An ageing population and expensive innovations in medicine put an increasing burden on already stressed healthcare budgets.

Read more

EHA Meeting Hub

Book a free-of-charge space at EHA2025 where you can meet your colleagues and further your work in person. What is the EHA Meeting Hub?The EHA Meeting Hub is a bookable on-site space at the EHA Congress venue in Milan.

Read more

Uptake of CAR T cell therapy in Europe

Feb 05 2019 Posted in Advocacy news Tagged CAR T

Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.

Read more

Press Release: Economic burden of blood disorders in EU is €23 billion

The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.

Read more